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(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en), [+ Digital Object Identifier link In pigs, treatment during the finishing with repartitioning doses of β-agonists has been associated with modifications of vascular microcirculation characterized by ulcerative lesions of the distal extremities (Dacasto et al., 1994; Poletto et al., 2009 ).
Elevated heart rate and increased peripheral catecholamine concentrations have been reported in pigs fed RAC (Marchant-Forde et al., 2003) . Additionally, hyperactivity, overreactivity to transport, and difficulty in handling have been also described (Marchant-Forde et al., 2003) . Treated pigs have a greater frequency of front and rear hoof lesions. They show an increase in Enterobacteriaceae shedding concentration at the first week of treatment, that progressively decreases until slaughter when it is less than in control animals (Poletto et al., 2009) . The same Authors reported also intensified aggression, especially in gilts (Poletto et al., 2010a,b) , probably due to reduced expression of serotonergic genes detected in the brain (Poletto et al., 2011) . The only macroscopic modification observed so far in RAC treated pigs is a decrease in the relative weight of thyroid glands (Ungemach, 2005) . The only histopathological finding reported in the same species is increased liver glycogen in periportal hepatocytes of a few pigs at high doses (Williams, 1987) .
Ractopamine-induced changes have also been investigated in cattle. To date, no adverse effects of RAC supplementation on cattle behaviour have been reported (Baszczak et al., 2006) . No changes on blood gas, blood electrolyte, or blood metabolite values have been observed (Abney, 2006) . Decrease of ruminal ammonia and amino acid concentration affecting fermentation of ruminal microflora have been recently reported (Walker and Drouillard, 2010) . The aim of this study was to investigate clinical, macroscopic and histopathological changes induced by RAC treatment in finishing pigs to identify possible biomarkers of illegal treatment and, therefore, to improve the surveillance methods at slaughtering.
Materials and methods
The study protocol adhered to national Animal Welfare Guidelines. 
Animals and treatment
A total of 32 eight-month-old Landrace x Large White pigs were used for the experiment. They were randomly divided into 4 groups of 8 animals, composed of 4 neutered males and 4 females each.
The animals were acclimated for one month (pre-treatment period); at the beginning of this period a parasitosis treatment was performed, using Ivermectin at a concentration of 10 mg/ 30 kg. At the end of the pre-treatment period (T0; -1 day prior the feeding trial), each group of pigs was allocated into 1 pen composed of 8 adjacent boxes, which housed 1 pig per box. At T1 animals were then euthanized in accordance with ethical guidelines.
Blood collection and chemistry analysis
At T0 and T1, 10 ml of blood samples were collected in test tube for serum, to evaluate pre-treatment and post-treatment complete blood count (CBCs), thyroid stimulating hormone (TSH) and triiodothyronine (T 3 ) blood levels.
Blood samples were centrifuged at 3000 g force for 10 minutes at room temperature, and serum aliquots were stored at -80 °C for further analysis.
Cardiac instrumental evaluation
At T0 and T1 the anesthetized pigs were submitted to electrocardiographic (ECG-P-power 40, Differences in heart rate (HR) were evaluated.
Pathological investigations
A complete necropsy of the pigs was performed. Skin, fat, muscle (longissimus dorsi), tonsils, thymus gland, mammary gland, thyroid, trachea, esophagus, heart, lung, stomach, small intestine, colon, liver, spleen, pancreas, kidney, adrenal gland, mesenteric lymph node, ovary, prostate, pituitary gland and eye were examined macroscopically and samples of each tissue were collected.
Thyroids were measured by means of a calliper, and weighed. Tissue samples were stored in 10% neutral buffered formalin for further evaluation.
After fixation and removal of extracardiac structures, total heart weight was measured. The total length (from the atrioventricular sulcus to the apex) and the right and left ventricular thickness at the insertion of the papillary muscle were estimated. Cross-sections of the left and right ventricular wall and the IVS at the insertion of the papillary muscle were prepared for histological examination.
All formalin-fixed tissues were processed for histological examination. Briefly, samples were dehydrated using ethanol at increasing concentrations and xilol solutions. At this stage they were paraffin embedded and 4-5 μm sections were obtained using a microtome (Leica Microsystems, Wetzlar, Germany).
The sections were then stained with hematoxylin/eosin and examined under a light microscope by two pathologists. Observed lesions were classified using a semiquantitative scoring system. 4 (300-400 cells); 5 (>400 cells).
Blood chemistry
CBC was performed using an ADVIA®120 Hematology System (Siemens Diagnostics, Erlangen, Germany).
Plasma TSH and T 3 concentrations were measured using commercial radioimmunoassay kits (Izotop, Budapest, Hungary). The intra-and inter-assay coefficients of variations were 4.6 ±0.7%
and 7.5 ±1.2% for T 3 and 2.7 ±0.1% and 8.5 ± 1.6% for TSH, respectively.
Statistical analysis
To assess normal distribution of data, the Shapiro-Wilk Normality test was performed. Metric data are presented as means ± standard error of mean (SEM).
To investigate for possible differences in scores attributable to histopathological lesions, a non-parametric Kruskal-Wallis test was performed. Correlation between histopathological lesions and groups (RAC dosages) was evaluated using the non-parametric Spearman Rank Correlation 
Results

Clinical observations
None of the animals showed any signs of clinical disease during the study period.
No significant difference in weight increase among the treatment groups was observed (P = 0.27) ( Table 1) .
By contrast, a significant reduction in feed consumption between groups R10 and R40 was observed when considering all the experimental animals (Pb0.05) (Fig. 1) . No statistically significant difference in CBCs was observed among groups.
Echocardiographic assessment at both T0 and T1 revealed tricuspid insufficiency in nine pigs and aortic insufficiency in five. None of the valvular insufficiencies was hemodynamically significant, the regurgitant jet (evaluated with color-Doppler) was very small, end peak velocity flow very low. A minimal amount of pleural effusion was detected in two pigs at the end of the study. No arrhythmias or differences in heart rate (HR) were found in any group at either assessment. There was no statistically significant difference in echocardiographic parameters among groups at T0 (P>0.05; Table 3 ).
The ventricular internal dimensions were significantly (P = 0.01) increased at T1 as compared with T0 values in group R20, as was LVM, with significant increases noted in both group R20 (P = 0.01) and group R10 (P = 0.05).
Inter-group evaluation showed a significant increase in left ventricular internal dimensions in group R10 with respect to group R40 (P = 0.02) and group R0 (P = 0.01) ( Table 3) . Table 3 Echocardiographic parameters in pigs treated with different RAC a dosages. Table 4 reports total heart weight and macroscopic heart measurements. A significant (Pb0.05) decrease in heart weight was observed in group R40 with respect to groups R0 and R10. Heart length was significantly increased in group R10 (Pb0.05).
Pathological lesions
A statistically significant (Pb0.05) difference in thyroid weight between groups R10 and R40
was observed when considering all the experimental animals. The mean values ± SEM for the different groups were: R0: 10.48±0.57; R10 11.09 ± 0.69; R20:9.19± 0.53 and R40:8.69 ± 0.31 g, respectively. Fig. 2 shows the gross appearance of thyroid gland of two pigs treated with R10 and R40 doses.
Histologically, no lesions potentially associated with treatment were observed in the skin, fat, muscle (longissimus dorsi), mammary gland, thyroid, trachea, oesophagus, heart, lung, stomach, intestine, pancreas, kidney, adrenal gland, pituitary gland, or eye.
Hepatic glycogenosis was observed in all animals, but no significant differences among groups were seen (P>0.05) (data not shown).
Eosinophilic cell infiltrates were found in the mesenteric lymph nodes, tonsils and in the substantia medullaris of the thymus of all RAC-treated animals. Eosinophils were sometimes degranulated with focal or multifocal distribution or organized in small clusters in some cases. In some instances, eosinophilic cells were detected in the spleen and the interfollicular spaces, where rarefaction of red pulp was present. Eosinophils were also present in the ovary, particularly around the follicles at different levels of development. There was a significant linear correlation between eosinophil infiltration in the thymus and RAC treatment (P = 0.014; Rs = 0.49) (Fig. 3) . Table 4 Heart dimensions and weight in pigs treated with different RAC a dosages. Fig. 2 . Gross appearance of a thyroid gland from a pig treated with R10 dose (10 ppm RAC) (a) (11.7 g) and a pig treated with R40 dose (40 ppm RAC) (b) (7.12 g), respectively. The prostate epithelium showed grade 1 hyperplastic lesions in only six RAC-treated animals, without differences among RAC treatment dosage groups.
No other significant associations between groups and pathological features were detected (P>0.05).
No other significant correlations between groups and pathological features were detected (P>0.05).
In the RAC-treated animals, the urethral epithelium showed different grades of hyperplasia (Figs.
4 and 5). Scattered metaplastic cells associated with moderate/severe hyperplasia were also present in three RAC-treated pigs.
The Kruskal-Wallis test revealed a statistically significant difference among the RAC-treated groups for the median
Blood hormone concentrations
At T0 blood hormone concentrations were evaluated on 8 animals in order to obtain pre-treatment basal values. The mean values ± SEM for T 3 and TSH blood levels were 6.95 ± 0.4 pmol/L and 0.22 ± 0.04 μIU/ml, respectively.
AtT1, blood T 3 concentrations were significantly reduced in the RAC-treated animals; no statistically significant differences in TSH levels were observed among the RAC-treated animals (Table 5 ).
Discussion
The present study investigated the clinical, macroscopical and histopathological changes induced by RAC treatment in the finishing pigs.
The use of RAC as a feed additive for growth-promoting purposes in fattening pigs and cattle is licensed in several countries, including the United States, Canada, Japan and Mexico.
In the USA the legal label for RAC feeding ranges between 5 and 10 mg/kg (ppm) fed, for the last 18
to 40 kg before slaughter at a constant concentration or as a "step-up" feeding program.
In the European Community, the Council Directive 96/22/EC banned the use of ß-agonists in livestock as growth promoting. Nevertleless these drugs are still used illegally, particularly by livestock producers. As a consequence, the identification of markers of the use of these drugs is important to identify at the slaughter an illegal treatment. The results of the present study suggest that high doses of RAC in pigs do not induce a significant increase in body weight, by contrast a statistically significant decrease in feed consumption was observed. This finding is in line with previously published data and confirms, in part, the growth-promoting effects of RAC in this species (Apple, 2007; Fernandez-Duenas et al., 2008) . The limited improvements in live weight could depend to the high dose of the β-agonist for a long period as it was reported by Abney (2006) in cattle. In fact, in these species short-term treatment causes improvements in weight gain more positive than studies of longer duration.
These findings might indicate that longer exposure to β-agonists may induce desensitization and thereby minimize any apparent advantages in average daily gain (ADG) (Abney, 2006).
Short-term treatment causes improvements in weight gain more positive than studies of longer duration. These findings might indicate that longer exposure to β-agonists may induce desensitization and thereby minimize any apparent advantages in average daily gain (ADG) (Abney, 2006) .
The modifications in heart weight and length observed in RAC-treated animals may be attributed to long-term stimulation of the adrenergic system. In rodents and other mammals, sustained activation of the β-adrenergic system by chronic administration of β-adrenergic agonists is a typical and well-characterised model of left ventricular hypertrophy (Mikusova et al., 2009; Osadchii et al., 2007) . In our study, however, the cardiac morphological changes were dose-independent. Echocardiographic evaluation showed an increase in left ventricular mass (LVM) in groups R10 and R20 at T1 but not in group R40. Although our data suggest that low-dose RAC treatment can induce eccentric hypertrophy, variations in heart weight and dimension cannot be specifically ascribed to RAC treatment or considered as a marker of illegal treatment with the drug. The dose-independent effect on heart weight and length could be partially due to a phenomenon of desensitization or down-regulation of cardiac beta-adrenoceptors. The down regulation of cardiac beta-adrenoceptors has in fact already been observed in other species such as cattle (Badino et al., 2008; Odore et al., 2007) .
Despite the fact that no statistically significant differences were observed in blood chemistry values among the four groups, all treated animals showed a certain degree of eosinophilic cell infiltration in the lymphoid organs. The increase in eosinophil circulating number and/or in tissue eosinophils, is associated with a wide variety of parasitic infestation, allergic responses, neoplasms, connective tissue disorders, medications and endocrinopathies (Bochsler and Slauson, 2002; Gotlib, 2005) . In our study, the animals showed no clinical signs of hypersensitivity reaction and all had received antiparasitic drugs before the beginning of RAC administration. It is known that, in vitro, treatment with β2-agonists causes a dose-related delay in eosinophil apoptosis, whereas β-blockers reduce their number (Kankaanranta et al., 2000) . On the basis of our results, the presence of eosinophil infiltrates in lymphoid organs should be carefully evaluated in cases of suspected illegal treatment with RAC, even if the role of RAC in the pathogenesis of eosinophilia should be further investigated. Macroscopically, the thyroid lesions partially confirm those described in literature (Ungemach, 2005) . The thyroid glands weight of the animals treated with 20 and 40 ppm of RAC were lower as compared with the controls and 10 ppm dose, suggesting that high RAC doses decrease thyroid weight. Histologically, no lesions were observed. It has been noted that sympathetic activity in thyroids contributes to gland enlargement and may modulate tissue responsiveness to thyroid hormones (Young et al., 2005) . However, whether the sympathetic effects involve changes in blood flow or in thyroid cell number or function is presently unknown.
The effects of RAC treatment on blood thyroid hormone levels have never been investigated in pigs so far. Clenbuterol administration reduces thyroid hormones in sheep and rats (Cardoso and Stock, 1998; Cardoso and Taveira, 2002) but not in broilers (Buyse et al., 1991) . Our data suggest that RAC treatment at 20 and 40 ppm induces a decrease in circulating T 3 levels. It has been postulated that specific interactions between the adrenergic system and thyroid function take place (Silva and Bianco, 2008) . The two systems act synergistically to allow the body to adapt to different environmental stimuli. Specifically, thyroid hormones increase the cell's capacity to respond to most catecholamine actions. On the other hand, catecholamines released by the sympathetic nerves can stimulate in a tissue-specific manner the conversion of T 4 into the more active T 3 .
Recently, it has been shown that thyroid hormone homeostasis regulation is mediated by the activation of both α-and β-adrenoceptors and involves the modulation of deiodinase type II activity, the enzyme responsible for the conversion of T 4 into T 3 (Kundu et al., 2009 ). These observations seem to disagree with the reduced T 3 concentrations found in the RAC-treated animals in our study. However, because α-adrenergic agonists inhibit the TSH-stimulated release of thyroid hormones and because of a predominance of α 2 -adrenoceptors in porcine thyroid, the reduction in circulating T 3 levels could be due to stimulation of α-adrenoceptors (Murakietal., 1982 (Murakietal., ,1984 . At repartitioning dosages, β-agonist affinity for β-AR subtypes could be partially reduced. Nevertheless, due to the individual variability in hormone concentrations, further studies are needed to confirm this hypothesis.
The urethral epithelium of the RAC-treated animals showed hyperplasia, sometimes associated with metaplasia. Cytoplas-matic vacuolization of urethral cells in some tissue samples was also detected. Hyperplasia of the prostatic epithelium was less frequent and mild.
To our knowledge, there are no published data on the effects of RAC treatment on the reproductive system in swine. In cattle, reproductive system modifications have been described following treatment with steroid hormones (Biolatti et al., 2003) . Moreover, prolonged clenbuterol exposure has been observed to induce pathological modifications of the female reproductive system, increased oestrogen and progesterone receptor concentrations, and a marked decrease in β-adrenoceptors in the heart, bronchial tubes and brain of veal calves (Odore et al., 2007; Re et al., 1995 Re et al., , 1997 . By contrast, Schiavone et al. (2004) found a down-regulation of androgen receptors in the male reproductive system of broilers treated with repartitioning doses of clenbuterol. The hypothesis that the modifications induced by steroid hormone receptor concentrations could be ascribed to cross-talk between the steroid and the cate-cholaminergic systems is supported by the observation that the administration of propranolol, a β-adrenergic blocker, inhibits the up-regulation of estrogen and progesterone receptors induced by clenbuterol (Re et al., 1993) .
Conclusion
The results of this study suggest that the most significant changes associated with the use of repartitioning doses of RAC in pigs involve the endocrine glands and the male lower urinary tract.
The lesions observed in prostate and urethral epithelium can be considered as adaptative reversible lesions induced by RAC treatment. No pathological features are reported in the thyroid despite the decrease in thyroid hormone concentrations. The role of RAC in the determinism of eosinophilic infiltration in lymphoid organs and in the ovary of gilts remains to be clarified.
Additional research on a larger group of pigs is needed to define the biomolecular mechanisms underlying the observed lesions.
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